Remdesivir Enters Clinical Trials as COVID-19 Treatment

April 13, 2020

Remdesivir Enters Clinical Trials as COVID-19 Treatment

Gilead Sciences has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the FDA’s rapid review and acceptance of Gilead’s IND filing. Enrollment of the clinical trial began in March — at present, 1000 participants will be entered into the trial. Yourway is committed to advancing trials and has full DTP capacity, which is particularly relevant given the stay-home-orders in place across countries and states.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply Europe

February 24-26, 2026
Hyatt Regency, Barcelona Tower

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat

Hello! How can I help you?